You are here

CRISPR

What to know about the U.K.’s approval of the first CRISPR treatment for diseases

What to know about the U.K.’s approval of the first CRISPR treatment for diseases

Nature

Vertex Pharmaceuticals

CRISPR Therapeutics

Flag link:

Vertex, CRISPR Win World’s First Approval for CRISPR-Edited Therapy from UK

Vertex, CRISPR Win World’s First Approval for CRISPR-Edited Therapy from UK

BioSpace

Vertex Pharmaceuticals

CRISPR Therapeutics

beta thalassemia

Flag link:

Cell & Gene Therapy Space Gears Up for First CRISPR Approval

Cell & Gene Therapy Space Gears Up for First CRISPR Approval

BioSpace

sickle cell disease

Vertex Pharmaceuticals

CRISPR Therapeutics

Flag link:

As Vertex preps for exa-cel launch, exec touts 'very large' opportunity but tempers early expectations

As Vertex preps for exa-cel launch, exec touts 'very large' opportunity but tempers early expectations

Fierce Pharma

Vertex Pharmaceuticals

Flag link:

Tracking the FDA’s meeting on Vertex, CRISPR’s sickle cell therapy

Tracking the FDA’s meeting on Vertex, CRISPR’s sickle cell therapy

BioPharma Dive

Vertex Pharmaceuticals

sickle cell disease

Flag link:

FDA Flags Off-Target Effects of Vertex, CRISPR’s Sickle Cell Therapy Ahead of Adcomm

FDA Flags Off-Target Effects of Vertex, CRISPR’s Sickle Cell Therapy Ahead of Adcomm

BioSpace

Vertex Pharmaceuticals

sickle cell disease

Flag link:

Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing

Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing

Investors Business Daily

transthyretin amyloidosis with cardiomyopathy

Flag link:

VedaBio Launches with $40+ Million Toward a CRISPR Molecular Detection Platform

VedaBio Launches with $40+ Million Toward a CRISPR Molecular Detection Platform

Genetic Engineering News

molecular detection

Flag link:

A decade later, biotech’s CRISPR revolution is still going strong

A decade later, biotech’s CRISPR revolution is still going strong

BioPharma Dive

Flag link:

AbbVie Terminates Collaboration and License Agreement with Caribou Biosciences

AbbVie Terminates Collaboration and License Agreement with Caribou Biosciences

Best Stocks

Caribou Biosciences

Flag link:

Why Shares of Tango Therapeutics Climbed This Week

Why Shares of Tango Therapeutics Climbed This Week

Motley Fool

Tango Therapeutics

clinical trials

Flag link:

First-ever CRISPR-CAS9 therapy, exa-cel, shows promising results

First-ever CRISPR-CAS9 therapy, exa-cel, shows promising results

Clinical Trials Arena

Vertex Pharmaceuticals

beta thalassemia

Flag link:

This Scientist Is Building Custom Gene-Editing Tools—And Stands To Make Billions

This Scientist Is Building Custom Gene-Editing Tools—And Stands To Make Billions

Forbes

Scribe Therapeutics

Flag link:

CRISPR on the Cusp: The Promise and the Pain Points

CRISPR on the Cusp: The Promise and the Pain Points

BioSpace

Intellia Therapeutics

Flag link:

Patients attack-free a year after receiving Intellia's hereditary angioedema CRISPR med

Patients attack-free a year after receiving Intellia's hereditary angioedema CRISPR med

Fierce Biotech

Intellia Therapeutics

hereditary angiodema

Flag link:

Landmark approval for Vertex's CRISPR drug 2 steps closer after trial wins, PDUFA date granted

Landmark approval for Vertex's CRISPR drug 2 steps closer after trial wins, PDUFA date granted

Fierce Biotech

Vertex Pharmaceuticals

CRISPR Therapeutics

sickle cell disease

beta thalassemia

Flag link:

BIO: Caribou tries to 'go where the puck is going' by taking on cell therapy rivals on home ice

BIO: Caribou tries to 'go where the puck is going' by taking on cell therapy rivals on home ice

Fierce Biotech

Caribou Biosciences

Flag link:

Scribe's CRISPR tech Prevails in new $1.5B biobucks deal with Lilly unit

Scribe's CRISPR tech Prevails in new $1.5B biobucks deal with Lilly unit

Fierce Biotech

Scribe Therapeutics

Prevail Therapeutics

Jennifer Doudna

Flag link:

Function Oncology raises $28M to use CRISPR to tailor cancer diagnosis and treatment

Function Oncology raises $28M to use CRISPR to tailor cancer diagnosis and treatment

BioPharma Dive

Function Oncology

Flag link:

Function Oncology raises $28M to use CRISPR to tailor cancer diagnosis and treatment

Function Oncology raises $28M to use CRISPR to tailor cancer diagnosis and treatment

Medtech Dive

Function Oncology

Flag link:

Pages